Spyre Therapeutics Appoints Dr. Sandra Milligan to Board

Spyre Therapeutics, a development-stage biotechnology company focused on advancing treatments for inflammatory bowel disease (IBD), has appointed Dr. Sandra Milligan, M.D., J.D., as a new member to its board of directors. Dr. Milligan brings with her a wealth of experience, having previously held leadership roles at various biopharmaceutical companies, including President of Aspira Women’s Health and Head of Research and Development at Organon & Co.

Dr. Milligan's appointment follows the departure of Russell Cox, whose board term ended on May 13, 2024. Jeffrey Albers, a current board member, has been appointed as the new chairman in connection with Cox's departure.

Spyre Therapeutics is focused on developing next-generation IBD products through antibody engineering, rational therapeutic combinations, and precision medicine approaches. The company's pipeline includes extended half-life antibodies targeting α4b7, TL1A, and IL-23.

This appointment underlines Spyre Therapeutics' commitment to scientific excellence and patient-centric innovation as it continues to progress novel antibody therapies targeting α4b7 and TL1A into clinical studies in the upcoming months.

It's worth noting that Spyre Therapeutics' stock is listed on the NASDAQ under the ticker symbol SYRE, and it continues to be an active player in the biotechnology space with a focus on IBD treatment advancements. The market has reacted to these announcements by moving the company's shares -5.3% to a price of $37.21. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.